Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc., a company specializing in medical devices and procedures for treating sleep-disordered breathing, has filed an amended Schedule 13G/A with the SEC, indicating changes in ownership by significant shareholders. The filing, dated December 31, 2023, and submitted on February 14, 2024, reveals that Coronado V Partners, LLC and R. Kirk Huntsman, the President of Coronado V Partners, LLC, collectively hold a significant portion of the company's shares. Coronado V Partners, LLC owns 69,600 shares, representing 3.2% of the company's common stock, while R. Kirk Huntsman individually holds 94,794 shares, accounting for 4.3% of the common stock. The total shares outstanding of Vivos Therapeutics' common stock are 2,207,651 as of February 13, 2024. The filing also notes that the reported share amounts and percentages reflect the effects of a 1-for-25 reverse stock split that took effect on October 25, 2023. Additionally, the filing indicates that R. Kirk Huntsman has ceased to be the beneficial owner of more than five percent of the class of securities.
Vivos Therapeutics, Inc., a company specializing in medical devices and procedures for treating sleep-disordered breathing, has filed an amended Schedule 13G/A with the SEC, indicating changes in ownership by significant shareholders. The filing, dated December 31, 2023, and submitted on February 14, 2024, reveals that Coronado V Partners, LLC and R. Kirk Huntsman, the President of Coronado V Partners, LLC, collectively hold a significant portion of the company's shares. Coronado V Partners, LLC owns 69,600 shares, representing 3.2% of the company's common stock, while R. Kirk Huntsman individually holds 94,794 shares, accounting for 4.3% of the common stock. The total shares outstanding of Vivos Therapeutics' common stock are 2,207,651 as of February 13, 2024. The filing also notes that the reported share amounts and percentages reflect the effects of a 1-for-25 reverse stock split that took effect on October 25, 2023. Additionally, the filing indicates that R. Kirk Huntsman has ceased to be the beneficial owner of more than five percent of the class of securities.
专门从事治疗睡眠呼吸障碍的医疗器械和手术的公司Vivos Therapeutics, Inc. 已向美国证券交易委员会提交了经修订的附表13G/A，表明大股东的所有权发生了变化。这份日期为2023年12月31日并于2024年2月14日提交的文件显示，Coronado V Partners, LLC和Coronado V Partners, LLC总裁R. Kirk Huntsman共同持有该公司的很大一部分股份。Coronado V Partners, LLC拥有69,600股股票，占公司普通股的3.2％，而R. Kirk Huntsman个人持有94,794股股票，占普通股的4.3％。截至2...展开全部
专门从事治疗睡眠呼吸障碍的医疗器械和手术的公司Vivos Therapeutics, Inc. 已向美国证券交易委员会提交了经修订的附表13G/A，表明大股东的所有权发生了变化。这份日期为2023年12月31日并于2024年2月14日提交的文件显示，Coronado V Partners, LLC和Coronado V Partners, LLC总裁R. Kirk Huntsman共同持有该公司的很大一部分股份。Coronado V Partners, LLC拥有69,600股股票，占公司普通股的3.2％，而R. Kirk Huntsman个人持有94,794股股票，占普通股的4.3％。截至2024年2月13日，Vivos Therapeutics普通股的已发行总股数为2,207,651股。该文件还指出，报告的股票金额和百分比反映了2023年10月25日生效的1比25反向股票拆分的影响。此外，该文件显示，R. Kirk Huntsman已不再是该类别超过5％的证券的受益所有人。
有用
没用